Cargando…

IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells

Hypersecretion is the major symptom of functional neuroendocrine tumours. The mechanisms that contribute to this excessive secretion of hormones are still elusive. A key event in secretion is the exit of secretory products from the Golgi apparatus. ADP-ribosylation factor (Arf) GTPases are known to...

Descripción completa

Detalles Bibliográficos
Autores principales: Münzberg, Christin, Höhn, Katharina, Krndija, Denis, Maaß, Ulrike, Bartsch, Detlef K, Slater, Emily P, Oswald, Franz, Walther, Paul, Seufferlein, Thomas, von Wichert, Götz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420598/
https://www.ncbi.nlm.nih.gov/pubmed/25754106
http://dx.doi.org/10.1111/jcmm.12473
_version_ 1782369753329827840
author Münzberg, Christin
Höhn, Katharina
Krndija, Denis
Maaß, Ulrike
Bartsch, Detlef K
Slater, Emily P
Oswald, Franz
Walther, Paul
Seufferlein, Thomas
von Wichert, Götz
author_facet Münzberg, Christin
Höhn, Katharina
Krndija, Denis
Maaß, Ulrike
Bartsch, Detlef K
Slater, Emily P
Oswald, Franz
Walther, Paul
Seufferlein, Thomas
von Wichert, Götz
author_sort Münzberg, Christin
collection PubMed
description Hypersecretion is the major symptom of functional neuroendocrine tumours. The mechanisms that contribute to this excessive secretion of hormones are still elusive. A key event in secretion is the exit of secretory products from the Golgi apparatus. ADP-ribosylation factor (Arf) GTPases are known to control vesicle budding and trafficking, and have a leading function in the regulation of formation of secretory granula at the Golgi. Here, we show that Arf1 is the predominant Arf protein family member expressed in the neuroendocrine pancreatic tumour cell lines BON and QGP-1. In BON cells Arf1 colocalizes with Golgi markers as well as chromogranin A, and shows significant basal activity. The inhibition of Arf1 activity or expression significantly impaired secretion of chromogranin A. Furthermore, we show that the insulin-like growth factor 1 (IGF-1), a major regulator of growth and secretion in BON cells, induces Arf1 activity. We found that activation of Arf1 upon IGF-1 receptor stimulation is mediated by MEK/ERK signalling pathway in BON and QGP-1 cells. Moreover, the activity of Arf1 in BON cells is mediated by autocrinely secreted IGF-1, and concomitantly, autocrine IGF1 secretion is maintained by Arf1 activity. In summary, our data indicate an important regulatory role for Arf1 at the Golgi in hypersecretion in neuroendocrine cancer cells.
format Online
Article
Text
id pubmed-4420598
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-44205982015-05-12 IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells Münzberg, Christin Höhn, Katharina Krndija, Denis Maaß, Ulrike Bartsch, Detlef K Slater, Emily P Oswald, Franz Walther, Paul Seufferlein, Thomas von Wichert, Götz J Cell Mol Med Original Articles Hypersecretion is the major symptom of functional neuroendocrine tumours. The mechanisms that contribute to this excessive secretion of hormones are still elusive. A key event in secretion is the exit of secretory products from the Golgi apparatus. ADP-ribosylation factor (Arf) GTPases are known to control vesicle budding and trafficking, and have a leading function in the regulation of formation of secretory granula at the Golgi. Here, we show that Arf1 is the predominant Arf protein family member expressed in the neuroendocrine pancreatic tumour cell lines BON and QGP-1. In BON cells Arf1 colocalizes with Golgi markers as well as chromogranin A, and shows significant basal activity. The inhibition of Arf1 activity or expression significantly impaired secretion of chromogranin A. Furthermore, we show that the insulin-like growth factor 1 (IGF-1), a major regulator of growth and secretion in BON cells, induces Arf1 activity. We found that activation of Arf1 upon IGF-1 receptor stimulation is mediated by MEK/ERK signalling pathway in BON and QGP-1 cells. Moreover, the activity of Arf1 in BON cells is mediated by autocrinely secreted IGF-1, and concomitantly, autocrine IGF1 secretion is maintained by Arf1 activity. In summary, our data indicate an important regulatory role for Arf1 at the Golgi in hypersecretion in neuroendocrine cancer cells. BlackWell Publishing Ltd 2015-05 2015-03-08 /pmc/articles/PMC4420598/ /pubmed/25754106 http://dx.doi.org/10.1111/jcmm.12473 Text en © 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Münzberg, Christin
Höhn, Katharina
Krndija, Denis
Maaß, Ulrike
Bartsch, Detlef K
Slater, Emily P
Oswald, Franz
Walther, Paul
Seufferlein, Thomas
von Wichert, Götz
IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
title IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
title_full IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
title_fullStr IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
title_full_unstemmed IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
title_short IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
title_sort igf-1 drives chromogranin a secretion via activation of arf1 in human neuroendocrine tumour cells
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420598/
https://www.ncbi.nlm.nih.gov/pubmed/25754106
http://dx.doi.org/10.1111/jcmm.12473
work_keys_str_mv AT munzbergchristin igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT hohnkatharina igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT krndijadenis igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT maaßulrike igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT bartschdetlefk igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT slateremilyp igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT oswaldfranz igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT waltherpaul igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT seufferleinthomas igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells
AT vonwichertgotz igf1driveschromograninasecretionviaactivationofarf1inhumanneuroendocrinetumourcells